These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 26400622

  • 1. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.
    Waterman HR, Kapp LM, Munday A, Odem-Davis K, Zimring JC.
    Transfusion; 2016 Jan; 56(1):91-100. PubMed ID: 26400622
    [Abstract] [Full Text] [Related]

  • 2. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
    Gras C, Schulze K, Goudeva L, Guzman CA, Blasczyk R, Figueiredo C.
    Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
    [Abstract] [Full Text] [Related]

  • 3. CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice.
    Gilson CR, Patel SR, Zimring JC.
    Transfusion; 2012 Oct; 52(10):2209-19. PubMed ID: 22321003
    [Abstract] [Full Text] [Related]

  • 4. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M, Narra R, Selim M, Zimmerman MA, Kim J, Padmanabhan A, Hong JC.
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [Abstract] [Full Text] [Related]

  • 5. Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model.
    Gilson CR, Zimring JC.
    Transfusion; 2012 Apr; 52(4):849-59. PubMed ID: 21981241
    [Abstract] [Full Text] [Related]

  • 6. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.
    Muench MO, Heitman JW, Inglis H, Fomin ME, Marschner S, Goodrich RP, Norris PJ, Jackman RP.
    Transfusion; 2016 Jun; 56(6):1419-29. PubMed ID: 27028210
    [Abstract] [Full Text] [Related]

  • 7. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
    Poston JN, Jash A, Hannan LM, Hay AM, Usaneerungrueng C, Howie HL, Kapp LM, Zimring JC.
    Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
    [Abstract] [Full Text] [Related]

  • 8. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
    Figueiredo C, Blaszczyk R.
    J Stem Cells; 2014 Mar; 9(3):149-61. PubMed ID: 25157449
    [Abstract] [Full Text] [Related]

  • 9. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP, Nambiar A.
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [Abstract] [Full Text] [Related]

  • 10. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y.
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [Abstract] [Full Text] [Related]

  • 11. Can we "terminate" alloimmune platelet transfusion refractoriness?
    Vassallo RR, Norris PJ.
    Transfusion; 2016 Jan; 56(1):19-22. PubMed ID: 26756708
    [No Abstract] [Full Text] [Related]

  • 12. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, Shan X.
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [Abstract] [Full Text] [Related]

  • 13. Evidence-based platelet transfusion guidelines.
    Slichter SJ.
    Hematology Am Soc Hematol Educ Program; 2007 Dec; ():172-8. PubMed ID: 18024626
    [Abstract] [Full Text] [Related]

  • 14. A bead-based assay in the work-up of suspected platelet alloimmunization.
    Cooper N, Bein G, Heidinger K, Santoso S, Sachs UJ.
    Transfusion; 2016 Jan; 56(1):115-8. PubMed ID: 26545411
    [Abstract] [Full Text] [Related]

  • 15. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
    Jackman RP, Lee JH, Pei R, Bolgiano D, Lebedeva M, Slichter SJ, Norris PJ.
    Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
    [Abstract] [Full Text] [Related]

  • 16. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype.
    Sayeh E, Aslam R, Speck ER, Le-Tien H, Lazarus AH, Freedman J, Semple JW.
    Transfusion; 2004 Nov; 44(11):1572-8. PubMed ID: 15504162
    [Abstract] [Full Text] [Related]

  • 17. Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells.
    Aslam R, Speck ER, Kim M, Freedman J, Semple JW.
    Transfusion; 2008 Sep; 48(9):1778-86. PubMed ID: 18522705
    [Abstract] [Full Text] [Related]

  • 18. Dominant immune response to HLA-B57/B58 molecules after platelet transfusion.
    Coombs J, Ben Hassen L, Leclerc M, Tamagne M, Pannetier L, Khelfa M, Delorme A, Bocquet T, Maury S, Pirenne F, Ansart-Pirenne H, Vingert B.
    Transfusion; 2020 Dec; 60(12):2807-2814. PubMed ID: 33037638
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.